Moderna, Inc. (NASDAQ:MRNA) | WebDisclosure

Basculer en Français

10105	Companies
207046	Keywords
137188	Articles
109732	Press releases

Home
Companies
Moderna, Inc.

PRESS RELEASE

published on 02/01/2024 at 13:00, 2 years 1 month ago

Moderna to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
Moderna, Inc. to report Q4 and full year 2023 financial results and provide corporate update in live conference call and webcast on February 22, 2024. Archived webcast available for one year

Financial Results Conference Call Moderna Inc Webcast MRNA Medicine
PRESS RELEASE

published on 01/31/2024 at 23:45, 2 years 1 month ago

Moderna Named to Fortune's List of World's Most Admired Companies
Moderna, Inc. has been recognized on Fortune's World's Most Admired Companies list, positioning among the top-50 companies. The company focuses on mRNA medicine for disease prevention and treatment, recognized for innovation and public health impact

Moderna Inc. Fortune Most Admired Companies MRNA Medicine Corporate Reputation
PRESS RELEASE

published on 01/08/2024 at 13:00, 2 years 2 months ago

Moderna Provides Business and Pipeline Updates at 42nd Annual J.P. Morgan Healthcare Conference
Moderna, Inc. (NASDAQ: MRNA) announces impressive financial updates for 2023, with approximately $6.7 billion in product sales and an increased COVID-19 market share in the U.S. The company reiterates the expectation of approximately $4 billion in product sales for 2024, highlighting upcoming late-stage programs with anticipated milestones in 2024 and 2025. The nine late-stage programs include respiratory vaccines, next-generation COVID-19 vaccine, seasonal flu vaccine, combination vaccine against seasonal flu and COVID-19, cytomegalovirus (CMV) vaccine, individualized neoantigen therapy (INT), and rare disease therapeutics. Moderna focuses on returning to sales growth in 2025 and expects to break even in 2026 through product launches and disciplined investment. For further details, Jamey Mock will present an update on the Company and its pipeline of mRNA development programs at the 42nd Annual J.P. Morgan Healthcare Conference on January 8th, 2024, at 3:45 p.m. PT/6:45 p.m. ET.

Moderna Inc Financial Updates COVID-19 Market Share Late-stage Programs MRNA Development Programs
PRESS RELEASE

published on 12/20/2023 at 22:05, 2 years 3 months ago

Moderna to Present at the 42nd Annual J.P. Morgan Healthcare Conference
PRESS RELEASE

published on 12/15/2023 at 00:00, 2 years 3 months ago

Moderna Announces New England Journal of Medicine Publication of Pivotal Phase 3 Clinical Safety and Efficacy Data For MRNA-1345, The Company’s Investigational Respiratory Syncytial Virus (RSV) Vaccine
PRESS RELEASE

published on 12/14/2023 at 12:30, 2 years 3 months ago

Moderna And Merck Announce mRNA-4157 (V940) In Combination with Keytruda(R) (Pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Comp
PRESS RELEASE

published on 12/12/2023 at 14:00, 2 years 3 months ago

Moderna Announces Changes to Commercial Organization to Prepare for Multiple Product Launches in 2024 and 2025
PRESS RELEASE

published on 12/07/2023 at 13:00, 2 years 3 months ago

Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event
PRESS RELEASE

published on 11/14/2023 at 13:00, 2 years 4 months ago

Moderna to Host Second Environmental, Social and Governance (ESG) Investor Event on December 7th, 2023
PRESS RELEASE

published on 11/08/2023 at 22:15, 2 years 4 months ago

Moderna to Present at Upcoming Conferences in November 2023

Accesswire

Published on 03/27/2026 at 15:35, 1 hour 51 minutes ago

SouthGobi Announces Fourth Quarter and Full Year 2025 Financial and Operating Results
Published on 03/27/2026 at 12:30, 4 hours 56 minutes ago

Pasinex Closes First Tranche of Over-Subscribed Non-Brokered Private Placement
Published on 03/27/2026 at 12:00, 5 hours 26 minutes ago

Temas Appoints Scientific Advisory Board to Accelerate RCL Commercialisation and Global Development
Published on 03/27/2026 at 12:00, 5 hours 26 minutes ago

Athena Gold Announces Share Consolidation
Published on 03/27/2026 at 11:00, 6 hours 26 minutes ago

RE Royalties Announces Strategic Review to Evaluate Path for Long-Term Value Creation

View all ACCESSWIRE

EQS Group

Published on 03/27/2026 at 15:58, 1 hour 28 minutes ago

coinIX remains resilient in volatile market environment with balanced annual result | CEO Moritz Schildt sees entry-level prices in the crypto market
Published on 03/27/2026 at 15:50, 1 hour 36 minutes ago

EQS-Adhoc: Klöckner & Co SE: Worthington Steel announces intention to enter into a domination and profit and loss transfer agreement with Klöckner & Co SE
Published on 03/27/2026 at 15:05, 2 hours 21 minutes ago

Huawei's 6th Global Installer Summit: Gathering the Best Installers to Embrace Renewable Energy Opportunities in the AI Era
Published on 03/27/2026 at 14:31, 2 hours 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: JTC plc
Published on 03/27/2026 at 14:31, 2 hours 55 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Bluefield Solar Income Fund Limited

Les Echos

Published on 03/27/2026 at 07:00, 10 hours 26 minutes ago

WEB SA - CONVOCATION ASSEMBLEE GENERALE ORDINAIRE EXERCICE 2025 - 28/04/2026
Published on 03/26/2026 at 18:17, 23 hours 9 minutes ago

Eiffage se renforce au capital de Getlink et porte sa participation à 29,40 % du capital
Published on 03/26/2026 at 18:17, 23 hours 9 minutes ago

Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 18:00, 23 hours 26 minutes ago

Arrêté des comptes au 31 décembre 2025 et perspectives 2026
Published on 03/26/2026 at 18:00, 23 hours 26 minutes ago

Calendrier financier 2026

View all LES ECHOS COMFI WIRE